Gymnema sylvestreGurmar, 'sugar destroyer'

What it is

A woody climbing vine native to India, used in Ayurvedic medicine for centuries. Its Hindi name, gurmar, means sugar destroyer, which refers to the taste effect rather than to anything that happens in your blood.

The active compounds are gymnemic acids, a group of saponins extracted from the leaves. GS4 is the standardized extract used in the original research.

How gymnema works on sweet taste

This part is genuinely well understood, which is unusual for a botanical supplement.

Sweetness is detected by a receptor made of two subunits, T1R2 and T1R3. Work published in 2014 showed that gymnemic acids bind inside the transmembrane domain of the human T1R3 subunit, and that this binding site overlaps with the one used by lactisole, another sweet blocker. The effect is specific to the human receptor: in the same experiments gymnemic acids suppressed the human sweet receptor but not the mouse version.

Put a gymnema leaf or lozenge on your tongue and sugar becomes texture without flavour for up to about an hour. It is a striking thing to experience and it is entirely real. The effect is reversible: in the 2014 work, rinsing with a sugar-like compound called gamma-cyclodextrin cleared it from the receptor.

Two things worth knowing before you count on it. It blocks sweetness indiscriminately, so the dessert you were looking forward to tastes of nothing too. And it only works where it touches, meaning a swallowed capsule does not produce the taste effect at all. For cravings you need a lozenge, a chewable or the leaf.

How gymnema is supposed to work on blood sugar

Here the honest answer is that nobody has shown it, and the proposed mechanisms are plausible rather than demonstrated.

Three are usually offered. Gymnemic acids may interfere with sugar absorption in the intestine, reducing how much gets in. They may stimulate insulin release. And the 1990 researchers proposed, on the basis of rising insulin levels in their patients, that the extract might regenerate or repair pancreatic beta cells.

That last claim circulates widely and should be read carefully. It was a suggestion made in both 1990 studies, neither of them randomised, offered as an explanation of an observed rise in insulin. It has not been demonstrated in humans since, and a supplement that regrew beta cells would be among the most important findings in diabetes research. Treat it as a hypothesis from 1990, not a property of the plant.

What the glycemic trials actually show

The two studies everyone cites were published together in 1990. In the type 2 study, 22 patients already taking oral anti-hyperglycaemic drugs were given 400 mg a day of GS4 for 18 to 20 months. Blood glucose, HbA1c and glycosylated plasma proteins all fell, their conventional drug doses could be reduced, and five of the 22 came off their medication entirely while maintaining control.

Those are striking results and they come with a serious caveat: there was no control group, no blinding, and 22 participants. Being followed closely in a study for nearly two years can on its own improve diabetes control.

A meta-analysis published in 2021 pooled 10 studies and 419 participants and reported significant reductions in fasting glucose, post-meal glucose, HbA1c, triglycerides and total cholesterol. Read the method before the result: it calculated effects by comparing each study's post-treatment data against that study's own baseline, not against a control group. A before-and-after comparison cannot separate the supplement from everything else that happens when someone enrols in a diabetes trial. Heterogeneity between studies was also extreme, reaching 99 percent for HbA1c, which means the studies were measuring things so different that pooling them is of limited value.

A second meta-analysis, published in 2023, did use a control comparison. It pooled six randomised trials and found gymnema lowered fasting blood sugar, triglycerides, total and LDL cholesterol and diastolic blood pressure. Its authors were careful about what that means: the studies were of low quality, notably heterogeneous and drawn from a narrow range of participants, and they called for larger, longer, better trials before the effect could be considered established. A 2024 randomised study in 50 people with obesity, comparing gymnema with berberine for three months, also found gymnema lowered fasting glucose.

This is why this page rates the evidence as mixed rather than moderate. The direction of every result is favourable. The quality of the evidence behind them is not good enough to call it demonstrated.

Gymnema dangers and side effects

For most people, gymnema is not dangerous. The trials report it as well tolerated, and the most common complaint is digestive: in a 2024 randomised study, stomach symptoms were the most frequent side effect and eased during the first month. There are, though, specific risks worth knowing.

The real risk is specific: hypoglycaemia in people taking insulin or oral diabetes drugs. If gymnema does what it is proposed to do, promoting insulin release and reducing glucose absorption, then stacking it on medication that already lowers glucose is the scenario where it matters. The 1990 study is relevant here in an unexpected way: its participants needed their conventional drug doses reduced during the study. That is the effect working, and it is also exactly what would cause a problem in someone adjusting nothing.

So: if you take any glucose-lowering medication, this is a prescriber conversation and a glucose meter, not a self-start supplement. If you have type 1 diabetes, never reduce or stop insulin on your own because you are taking gymnema: one of the 1990 studies was in people on insulin, and cutting insulin without medical supervision risks diabetic ketoacidosis. If you take none of these medicines, the main thing you will notice is your dessert tasting of cardboard.

Liver injury is the rare one. The NIH's LiverTox database, which tracks drug and supplement liver injury, describes isolated rare reports of liver injury from products containing gymnema, with attribution to the herb usually weak. The best documented is a 2010 case report of toxic hepatitis in a person taking gymnema for type 2 diabetes, in which the authors noted they could find no earlier report linking it to liver injury. A 2022 report described two people who developed hepatitis followed by fatal bone marrow failure after taking gymnema together with two homeopathic remedies, so the gymnema cannot be singled out. Against the number of people who take it, this is a rare signal, not a pattern. Stop and see a doctor if you develop yellowing of the skin or eyes, dark urine, pale stools or pain under the right ribs.

Avoid in pregnancy and breastfeeding, for the ordinary reason that there is no safety data rather than any specific signal. And stop two weeks before surgery, as with anything that affects blood sugar.

Gymnema in blood sugar supplements

Gymnema is in both of the blood sugar products reviewed on this site, and in neither of them can you find out how much.

GlucoTrust lists it inside a proprietary blend with no amounts disclosed. Sugar Defender discloses something better and worse at the same time: its whole herbal blend is 200 mg a day shared between 22 ingredients, so even if gymnema were the largest component by far it could not reach the 400 mg the trials used.

That is the general shape of this category. The ingredient with the research is present, in a quantity that cannot be the one researched, and the label is arranged so you cannot tell. A single-ingredient product stating its gymnemic acid percentage costs less and tells you what you are taking.